Mereo BioPharma Group plc Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- Mereo BioPharma Group plc price/book ratio for the quarter ending 2026-06-30 was 9.23, a 76.87% decline year-over-year.
- Mereo BioPharma Group plc price/book ratio for the quarter ending 2026-03-31 was 7.89, a 73.50% decline year-over-year.
- Mereo BioPharma Group plc price/book ratio for the quarter ending 2025-12-31 was 8.08, a 81.86% decline year-over-year.
- Mereo BioPharma Group plc price/book ratio for the quarter ending 2025-09-30 was 35.17, a change of 78.75 year-over-year.
- Mereo BioPharma Group plc price/book ratio for fiscal 2026 was 9.23.
- Mereo BioPharma Group plc price/book ratio for fiscal 2025 was 8.08, a 81.86% decline from fiscal 2024.
- Mereo BioPharma Group plc price/book ratio for fiscal 2024 was 44.53.
- Mereo BioPharma Group plc price/book ratio for fiscal 2023 was 9.95.
- Available history
- 2021-12-31 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |